CMX-2043
Also known as: CMX2043, Ischemix CMX-2043
Source CMX-2043 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CMX-2043 is an investigational synthetic analogue of α‑lipoic acid designed as a cytoprotective agent. It is being studied for its ability to limit tissue damage caused by ischemia‑reperfusion and traumatic injury, with research focusing on cardiac procedures such as percutaneous coronary intervention (PCI) and on traumatic brain injury (TBI). The compound is administered by injection, primarily intravenously, and is not yet approved for any therapeutic indication.
Mechanism of Action
CMX-2043 acts as a potent antioxidant and anti‑apoptotic molecule. In vitro studies showed it enhances insulin‑receptor kinase activity, activates downstream Akt (protein kinase B) signaling, and reduces calcium overload. These effects are blocked by PI3‑kinase inhibition, indicating dependence on the PI3K/Akt pathway. Molecular docking suggests strong binding to human manganese superoxide dismutase (MnSOD), providing additional redox‑balancing activity. Together, these actions protect cells from oxidative stress and programmed cell death.
What the Research Shows
Preclinical work demonstrates CMX-2043 reduces myocardial infarct size and arrhythmia incidence in a rat model of cardiac ischemia‑reperfusion, with the greatest benefit when given 15 minutes before injury. A large‑animal porcine TBI study showed intravenous or subcutaneous dosing for five days limited brain swelling, preserved white‑matter integrity, and improved neurological and cognitive scores up to six weeks post‑injury. In humans, a phase 2a, double‑blind, placebo‑controlled trial (SUPPORT‑1) in 142 patients undergoing elective PCI reported significant reductions in CK‑MB and troponin T peaks at a 2.4 mg/kg IV dose, with no drug‑related serious adverse events. A phase 1 dose‑escalation study found the drug well‑tolerated, non‑mutagenic, and lacking off‑target receptor binding. In silico docking identified strong interaction with MnSOD, supporting a possible antioxidant mechanism beyond that of native lipoic acid.
Reported Benefits
Animal data suggest CMX-2043 can limit tissue damage after cardiac ischemia‑reperfusion and improve functional recovery after severe brain trauma. Early human evidence indicates it may reduce periprocedural myocardial injury markers during PCI, hinting at cardioprotective potential. The compound’s dual antioxidant and Akt‑activating actions may underlie these benefits, and its favorable safety profile in phase 1 testing supports further clinical evaluation.
Limitations of the Evidence
Efficacy in humans is based on a single phase 2a PCI trial with surrogate biomarker endpoints; no data on hard clinical outcomes such as mortality or long‑term cardiac function exist. Neuroprotective findings are limited to a porcine model, and translational relevance to human TBI remains unproven. Sample sizes are modest, and dosing regimens vary across studies, making optimal dosing unclear. The compound remains investigational with no regulatory approval.
Safety Considerations
Preclinical toxicology reported no mutagenicity, clastogenicity, or significant receptor binding, with NOAELs of 30 mg/kg in rats and >10 mg/kg in dogs. A phase 1 human trial reported no serious adverse events or dose‑limiting toxicities. Reported adverse effects are minimal, but the safety profile beyond short‑term exposure is unknown, and rare or long‑term toxicities have not been established. Use remains confined to clinical research settings.
How It Is Administered
CMX-2043 has been administered intravenously as a single bolus before PCI and repeatedly (IV or subcutaneous) in animal studies for several days. In rat cardiac studies, injections were given before, during, or after ischemia. Formulations are injectable solutions; no oral or other routes have been reported.
Routes of Administration
Goals & Uses
- Cardioprotection during PCICardiovascularModerate
- Mitochondrial ROS reductionAntioxidant/CytoprotectionModerate
- Renal protection during cardiac surgeryNephrologyModerate
- Reduction of ischemia-reperfusion injuryCardiovascular/SurgicalModerate
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Hypersensitivity to CMX-2043 or lipoic acid derivativesAllergyHigh
Adverse Effects
- Elevated liver enzymes (transient)HepaticRare
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Anticoagulants (e.g., heparin)Low
- Antioxidant supplements (e.g., alpha-lipoic acid, vitamin E)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
Regulatory Status
- European UnionUnknownNo EMA approval or IMPD publicly reported as of knowledge cutoff.
- United StatesInvestigationalStudied under IND; no FDA approval granted. Phase 2 trials completed without subsequent approval filing reported.
- United KingdomUnknownNo MHRA approval reported.
CMX-2043 has received no regulatory approval from FDA, EMA, or other major agencies. It has been studied under IND regulations in Phase 1 and Phase 2 trials. Development has been led by Ischemix Inc. No current approvals for any indication as of the knowledge cutoff.
Evidence & Sources
- Journal ArticleLowSchantz SL, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateTcheng JE, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleLowJavaid MS, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleLowLader AS, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleLowBaguisi A, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateKates SA, et al.2014-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is CMX-2043?
CMX-2043 is a synthetic analogue of α‑lipoic acid, classified as a cyclic peptide‑like cytoprotective agent under investigation for reducing ischemia‑reperfusion and traumatic injury damage.
Has CMX-2043 been approved for medical use?
No. CMX-2043 is currently investigational and has only been studied in early‑phase clinical trials and preclinical models.
What clinical evidence supports its use in heart procedures?
In the phase 2a SUPPORT‑1 trial, a single intravenous dose (2.4 mg/kg) given before elective PCI lowered CK‑MB and troponin T peaks compared with placebo, suggesting reduced myocardial injury.
Can CMX-2043 help after a traumatic brain injury?
In a pediatric porcine TBI model, five days of IV or subcutaneous CMX-2043 reduced brain swelling, preserved white‑matter integrity, and improved neurological and cognitive scores up to 42 days post‑injury.
What are the known safety concerns?
Preclinical studies showed no mutagenic or clastogenic effects, and a phase 1 human trial reported no serious adverse events. However, long‑term safety and rare adverse effects have not yet been established.
What is CMX-2043?
CMX-2043 is an investigational synthetic analogue of α‑lipoic acid designed as a cytoprotective agent. It is being studied for its ability to limit tissue damage caused by ischemia‑reperfusion and traumatic injury, with research focusing on cardiac procedures such as percutaneous coronary intervention (PCI) and on traumatic brain injury (TBI). The compound is administered by injection, primarily intravenously, and is not yet approved for any therapeutic indication.
What is CMX-2043 used for?
CMX-2043 is educationally associated with: Cardioprotection during PCI, Mitochondrial ROS reduction, Renal protection during cardiac surgery, Reduction of ischemia-reperfusion injury. Educational only — not medical advice.
How is CMX-2043 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of CMX-2043?
Reported adverse effects include: Elevated liver enzymes (transient), Injection site reactions, Headache, Hypotension, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid CMX-2043?
Recorded contraindications: Severe hepatic impairment, Hypersensitivity to CMX-2043 or lipoic acid derivatives. Consult a qualified clinician before use.